PitchBook年二季度美国公共PE和GP交易综述(英)

Q12025Q22025USPublic PE and GP Deal Roundup2Q2 2025 US PUBLIC PE AND GP DEAL ROUNDUPPitchBook Data, Inc.Nizar Tarhuni Executive Vice President of Research and Market IntelligenceMarina Lukatsky Global Head of Research, Credit and US Private EquityInstitutional Research GroupAnalysisGarrett Hinds Senior Research Analyst, Private Equity garrett.hinds@pitchbook.comJinny Choi Senior Research Analyst, Private Equity jinny.choi@pitchbook.comKyle Walters Research Analyst, Private Equity kyle.walters@pitchbook.comDataCharlie Farber Manager, Data Analysispbinstitutionalresearch@pitchbook.comPublishingReport designed by Josie Doan and Adriana HansenPublished on August 27, 2025Click here for PitchBook’s report methodologies.ContentsKey takeaways 3PE performance 5Deployment 7Realizations 9Fundraising 11Strategy expansion 17Share of AUM by manager and strategy 20GP deal activity 22GP stake transactions 23Operating results 24Stock performance and comparables 25Note: “PE” has a specific meaning for the seven major public alternative managers referenced in this report.1. Blackstone and Carlyle: “Corporate PE” as defined in company reports. 2. KKR: “Traditional PE” as defined in company reports. 3. Apollo: “Flagship PE” and “European principal finance” as defined in company reports. 4. Ares: “Corporate PE” and “special opportunities” as defined in company reports. 5. TPG: “Capital” and “growth” as defined in company reports. 6. Blue Owl: “PE” represents PitchBook estimates of ownership stakes held by “GP Strategic Capital” funds in managers primarily engaged in PE buyout and growth equity strategies.Note: “Private credit” has a specific meaning for the seven major public alternative managers referenced in this report.1. KKR: “Alternative Credit” as defined in company reports. 2. Ares: “US Senior Direct Lending” as defined in company reports. 3. Blue Owl: “Direct Lending Gross Returns” as defined in company reports. 4. Apollo: “Direct Origination” as defined in company reports. 5. Blackstone: “Private Credit” as defined in company reports. 6. Carlyle: “Global Credit” as defined in company reports. 7. TPG: “TPG AG Credit” as defined in company reports.3Q2 2025 US PUBLIC PE AND GP DEAL ROUNDUPShare of TTM capital raised by strategyPrivate equityReal estateCreditOther17.7%13.5%58.8%9.9%$710.3BSource: Company reports • Geography: Global • As of June 30, 2025Share of AUM by strategyPrivate equityReal estateCreditOther23.7%18.7%51.0%6.7%$4,139.0BSource: Company reports • Geography: Global • As of June 30, 2025Key takeawaysCredit returns lead: In Q2 2025, PE returns for the “Big Seven” public alternative managers held steady at robust levels, with a median TTM return of 10% for the second straight quarter and a 2.8% quarterly gain—an improvement from Q1’s 2%. These results continue to outpace the broader PE market, where one-year IRRs have slipped from 10.8% to 9.4%, though early 2025 data suggests recovery will remain uneven. The managers’ performance stil

立即下载
综合
2025-09-08
28页
3.02M
收藏
分享

PitchBook年二季度美国公共PE和GP交易综述(英),点击即可下载。报告格式为PDF,大小3.02M,页数28页,欢迎下载。

本报告共28页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
本报告共28页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
水滴研报所有报告均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
相关图表
SW 医药流通指标 2025H1 营业总收入规模企稳修复(单位:亿元)
综合
2025-09-08
来源:医药生物行业点评报告:中药及医药商业2025H1复盘:短期承压,静待花开
查看原文
2025H1 连锁药店头部上市公司基本放缓门店扩张步伐
综合
2025-09-08
来源:医药生物行业点评报告:中药及医药商业2025H1复盘:短期承压,静待花开
查看原文
2025Q2 药店头部企业营业总收入同比逐渐企稳 图4:2025Q2 药店头部企业净利率环比略有下降
综合
2025-09-08
来源:医药生物行业点评报告:中药及医药商业2025H1复盘:短期承压,静待花开
查看原文
2024Q4-2025Q1 全国零售药店数量出现负增长(单位:家)
综合
2025-09-08
来源:医药生物行业点评报告:中药及医药商业2025H1复盘:短期承压,静待花开
查看原文
中药公司公告 2025 上半年业绩,部分企业相对承压静待回暖
综合
2025-09-08
来源:医药生物行业点评报告:中药及医药商业2025H1复盘:短期承压,静待花开
查看原文
美国 LNG 长协价格测算(不含关税) 表4:美国 LNG 长协价格测算(含 25%关税)
综合
2025-09-08
来源:燃气Ⅱ行业跟踪周报:美国气价上涨,欧洲-中国气价持平,九丰能源一体化持续推进
查看原文
回顶部
报告群
公众号
小程序
在线客服
收起